Tryptase as a marker of severity of aortic valve stenosis.

Q2 Medicine

Clinical and Molecular Allergy Pub Date : 2018-08-07 eCollection Date: 2018-01-01 DOI:10.1186/s12948-018-0095-6

Laura M Losappio, Corrado Mirone, Michel Chevallard, Laura Farioli, Fabrizio De Luca, Elide A Pastorello

{"title":"Tryptase as a marker of severity of aortic valve stenosis.","authors":"Laura M Losappio, Corrado Mirone, Michel Chevallard, Laura Farioli, Fabrizio De Luca, Elide A Pastorello","doi":"10.1186/s12948-018-0095-6","DOIUrl":null,"url":null,"abstract":"Background: Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving also mast cells and their mediators, in particular tryptase. The aim of this study was to characterize the possible long-term prognostic role of tryptase in severe aortic valve stenosis.Case presentation: The baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital to undergo aortic valve replacement for severe acquired stenosis. Within 2 years after, the patients were evaluated for the occurrence of major cardiovascular events (MACE). The tryptase measurements were higher in patients experiencing MACE (10.9, 11.7 and 9.32 ng/ml) than in non-MACE ones (5.69 and 5.58 ng/ml).Conclusions: In patients affected with severe aortic stenosis, baseline serum tryptase may predict occurence of MACE. Further studies are needed to demonstrate the long-term prognostic role of this biomarker.","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"17"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0095-6","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-018-0095-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving also mast cells and their mediators, in particular tryptase. The aim of this study was to characterize the possible long-term prognostic role of tryptase in severe aortic valve stenosis.

Case presentation: The baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital to undergo aortic valve replacement for severe acquired stenosis. Within 2 years after, the patients were evaluated for the occurrence of major cardiovascular events (MACE). The tryptase measurements were higher in patients experiencing MACE (10.9, 11.7 and 9.32 ng/ml) than in non-MACE ones (5.69 and 5.58 ng/ml).

Conclusions: In patients affected with severe aortic stenosis, baseline serum tryptase may predict occurence of MACE. Further studies are needed to demonstrate the long-term prognostic role of this biomarker.

查看原文本刊更多论文

胰蛋白酶作为主动脉瓣狭窄严重程度的标志。

背景:严重主动脉瓣狭窄是成人代谢综合征患者死亡的最常见原因之一，代谢综合征与肥大细胞及其介质，特别是胰蛋白酶的炎症过程有关。本研究的目的是描述胰蛋白酶在严重主动脉瓣狭窄中可能的长期预后作用。病例介绍:连续5例因严重获得性主动脉瓣狭窄而入院行主动脉瓣置换术的患者，测定了基线血清胰蛋白酶。术后2年内评估患者主要心血管事件(MACE)的发生情况。MACE患者胰蛋白酶测定值(10.9、11.7和9.32 ng/ml)高于非MACE患者(5.69和5.58 ng/ml)。结论:在严重主动脉瓣狭窄患者中，基线血清胰蛋白酶可以预测MACE的发生。需要进一步的研究来证明这种生物标志物的长期预后作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Molecular Allergy Medicine-Immunology and Allergy

CiteScore

8.20

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.